Table 1.
Participant demographics
| Discovery study (n = 197) | Validation study (n = 200) | P value | |
|---|---|---|---|
| Age (years), mean ± SD | 71.1 ± 8.5 | 70.8 ± 7.9 | NS |
| Sex, female/male | 112/85 | 99/101 | NS |
| Race, White/Japanese/Other | 130/50/17 | 136/50/14 | NS |
| APOE ε4 status, − / + /NA | 123/71/3 | 114/86/0 | NS |
| Amyloid PET status, − / + | 97/100 | 100/100 | NS |
| Amyloid PET probe, FBB/FBP/FMM/NA | 124/27/46/0 | 124/22/45/9 | 0.023 |
| MMSE, mean ± SD | 26.4 ± 1.8 | 26.5 ± 1.8 | NS |
| CDR-SB, mean ± SD | 2.4 ± 1.0 | 2.5 ± 1.0 | NS |
| Centiloid unit, mean ± SD | 38.4 ± 50.0 (n = 180) | 41.4 ± 48.9 (n = 191) | NS |
| Clinical disease staging, MCI due to AD/mild AD | 157/40 | 160/40 | NS |
Significant differences between the discovery and validation studies were evaluated via the Student’s t-test for continuous measures and the χ.2 test for categorical variables
Abbreviations: PET Positron emission tomography, SD Standard deviation, NS Not significant, APOE Apolipoprotein E, NA not available, FBB Florbetaben, FBP Florbetapir, FMM Flutemetamol, MMSE Mini-Mental State Examination, CDR-SB Clinical Dementia Rating-Sum of Boxes, MCI Mild cognitive impairment, AD Alzheimer’s disease